BIOMARKER:

EGFR exon 18 mutation

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

C2 | Resistant

C3 | Resistant

C4 | Resistant

Show legend

Drug categories

EGFR

Tyrosine Kinase Inhibitors

Immunotherapy

Non Small Cell Lung Cancer

Lung Adenocarcinoma

bevacizumab + erlotinib

EGFR exon 18 mutation|Non Small Cell Lung Cancer|bevacizumab + erlotinib

afatinib

EGFR exon 18 mutation|Non Small Cell Lung Cancer|afatinib

erlotinib

EGFR exon 18 mutation|Non Small Cell Lung Cancer|erlotinib

neratinib

EGFR exon 18 mutation|Non Small Cell Lung Cancer|neratinib

bevacizumab + afatinib

EGFR exon 18 mutation|Lung Adenocarcinoma|bevacizumab + afatinib

FCN-411

EGFR exon 18 mutation|Non Small Cell Lung Cancer|FCN-411

EGFR inhibitor

EGFR exon 18 mutation|Non Small Cell Lung Cancer|EGFR inhibitor